Deregistered
Lannett filed to terminate its SEC registration on June 20, 2023.
The business overview below summarizes the 10-K filed August 25, 2022, which predates these events.
Sources: 15-12G (Jun 20, 2023)
Business Summary
Lannett Company, Inc. is a Philadelphia, Pennsylvania-based generic pharmaceutical company incorporated in Delaware (originally Pennsylvania, 1942). The company develops, manufactures, markets, and distributes generic versions of branded pharmaceutical products, focused exclusively on the U.S. market. Generics accounted for approximately 90% of U.S. prescriptions in the 12-month period ending June 30, 2022. Fiscal year 2022 total net sales were $340.6 million, reflecting the effects of an industry-wide generic drug pricing downturn that has pressured revenues in recent periods after growing from $12.1 million in fiscal year 2001.
Products & Services
- Markets more than 100 products, primarily oral solid and liquid generic medications (tablets, capsules, and liquid oral forms)
- Top products (~39% of fiscal 2022 sales):
- Amphetamine IR Tablets (generic Adderall) and Amphetamine ER Capsules — ADHD/narcolepsy
- Methylphenidate CD Capsules (authorized generic of Metadate CD) and Methylphenidate ER — ADHD
- Levothyroxine Capsules (generic...
AI-generated summary of Item 1 (Business) from the 10-K filed Aug 25, 2022 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Annual results · 10-K
Fiscal 2022- Revenue
- $340.6M
- Net loss
- -$231.6M
As reported in the fiscal 2022 annual report.